1. Home
  2. NRXP vs HHS Comparison

NRXP vs HHS Comparison

Compare NRXP & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRXP
  • HHS
  • Stock Information
  • Founded
  • NRXP 2015
  • HHS 1923
  • Country
  • NRXP United States
  • HHS United States
  • Employees
  • NRXP N/A
  • HHS N/A
  • Industry
  • NRXP Biotechnology: Pharmaceutical Preparations
  • HHS Advertising
  • Sector
  • NRXP Health Care
  • HHS Consumer Discretionary
  • Exchange
  • NRXP Nasdaq
  • HHS Nasdaq
  • Market Cap
  • NRXP 32.6M
  • HHS 30.3M
  • IPO Year
  • NRXP N/A
  • HHS N/A
  • Fundamental
  • Price
  • NRXP $3.24
  • HHS $4.03
  • Analyst Decision
  • NRXP Strong Buy
  • HHS
  • Analyst Count
  • NRXP 4
  • HHS 0
  • Target Price
  • NRXP $28.50
  • HHS N/A
  • AVG Volume (30 Days)
  • NRXP 204.8K
  • HHS 31.2K
  • Earning Date
  • NRXP 08-13-2025
  • HHS 08-07-2025
  • Dividend Yield
  • NRXP N/A
  • HHS N/A
  • EPS Growth
  • NRXP N/A
  • HHS N/A
  • EPS
  • NRXP N/A
  • HHS N/A
  • Revenue
  • NRXP N/A
  • HHS $181,355,000.00
  • Revenue This Year
  • NRXP N/A
  • HHS $6.54
  • Revenue Next Year
  • NRXP N/A
  • HHS N/A
  • P/E Ratio
  • NRXP N/A
  • HHS N/A
  • Revenue Growth
  • NRXP N/A
  • HHS N/A
  • 52 Week Low
  • NRXP $1.10
  • HHS $3.24
  • 52 Week High
  • NRXP $6.01
  • HHS $8.80
  • Technical
  • Relative Strength Index (RSI)
  • NRXP 53.62
  • HHS 40.53
  • Support Level
  • NRXP $2.90
  • HHS $3.61
  • Resistance Level
  • NRXP $3.53
  • HHS $4.05
  • Average True Range (ATR)
  • NRXP 0.20
  • HHS 0.57
  • MACD
  • NRXP -0.04
  • HHS 0.01
  • Stochastic Oscillator
  • NRXP 58.73
  • HHS 24.19

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

About HHS Harte-Hanks Inc.

Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.

Share on Social Networks: